KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Current Liabilities (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Total Current Liabilities for 9 consecutive years, with $190.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 23.88% year-over-year to $190.2 million, compared with a TTM value of $190.2 million through Sep 2025, up 23.88%, and an annual FY2024 reading of $160.4 million, up 6.93% over the prior year.
  • Total Current Liabilities was $190.2 million for Q3 2025 at Biocryst Pharmaceuticals, up from $139.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $190.2 million in Q3 2025 and bottomed at $85.2 million in Q1 2023.
  • Average Total Current Liabilities over 3 years is $131.2 million, with a median of $134.5 million recorded in 2024.
  • Peak annual rise in Total Current Liabilities hit 69.2% in 2024, while the deepest fall reached 6.93% in 2024.
  • Year by year, Total Current Liabilities stood at $150.0 million in 2023, then grew by 6.93% to $160.4 million in 2024, then grew by 18.61% to $190.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for BCRX at $190.2 million in Q3 2025, $139.9 million in Q1 2025, and $160.4 million in Q4 2024.